Hashimoto, Yoshitaka
Sakai, Ryosuke
Ikeda, Kenichiro
Fukui, Michiaki
Funding for this research was provided by:
Kowa Company. Ltd.
Article History
Received: 24 March 2020
Accepted: 16 June 2020
First Online: 30 June 2020
Ethics approval and consent to participate
: The survey was conducted with approval from Pearl IRB (IRB Study Number: 16-KAN-124). Written informed consent was obtained from all participants. The authors were granted access to NHWS data from Kantar Health for this research.
: Not applicable.
: K.I. is an employee of Kowa Pharma Co. Ltd., M.F. received research supports and honorarium from Kowa Pharma Co. Ltd. In addition, Y.H. received honoraria from Mitsubishi Tanabe Pharma Corp, and Novo Nordisk Pharma Ltd., and M.F. received grants from Takeda Pharma Co. Ltd., Sanofi K.K., Kissei Phama Co. Ltd., Mitsubishi Tanabe Pharma Corp, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co. Ltd., Daiichi Sankyo Co. Ltd., MSD K.K., Sanwa Kagagu Kenkyusho CO., LtD., Kowa Pharma Co. Ltd., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharma Co. Ltd., Eli Lilly Japan K.K., Taisho Pharma Co., Ltd., Tejin Pharma LtD., Nippon Chemiphar Co., Ltd., Johnson & Johnson k.k. Medical Co., Abbott japan Co. Ltd., and Terumo Corp., and received honoraria from Teijin Pharma Ltd., Arkray Inc., Kissei Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., Sanofi K.K., Takeda Pharma Co. Ltd., Astellas Pharma Inc., MSD K.K., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Daiichi Sankyo Co. Ltd., Ono Pharma Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Taisho Pharma Co., Ltd., Bayer Yakuhin, Ltd., AstraZeneca K.K., Mochida Pharma Co. Ltd., Abbott japan Co. Ltd., Eli Lilly Japan K.K., Medtronic Japan Co. Ltd., and Nipro Corp. outside the submitted work. R.S. has no potential conflict of interest.